Literature DB >> 3131160

Ovarian response of individuals to different doses of human menopausal gonadotropin.

C A Benadiva1, Z Ben-Rafael, J F Strauss, L Mastroianni, G L Flickinger.   

Abstract

Hormonal profiles were compared in 14 ovulatory women who were treated with two different doses of gonadotropins in successive in vitro fertilization cycles. All patients suffered from mechanical causes of infertility. Serum estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and progesterone (P) were measured daily during the follicular phase. Women were arbitrarily classified as high responders (E2 greater than 1000 pg/ml on the day of human chorionic gonadotropin administration, n = 8) or as low responders (E2 less than 1000 pg/ml, n = 6), according to the peak E2 levels during the cycle when they received 3 ampules of human menopausal gonadotropin (hMG). When patients were treated with 3 ampules of hMG, serum FSH, LH, and P concentrations increased significantly during the follicular phase in high responders but remained unchanged in low responders. When these patients were treated with 2 ampules of hMG, the temporal profiles of the hormones were similar, but the magnitude of increases in serum levels of gonadotropins and sex steroids was significantly reduced in high responders. The authors conclude that temporal individuality of endocrine profiles cannot be altered by varying the dose of gonadotropin. Increases in hormone levels accompanying a high response to hMG can, however, be dampened by lowering the dose. In contrast, hormone concentrations are not influenced by changing the dose of hMG in low responders.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3131160

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

Review 1.  Low- versus high-dose human menopausal gonadotropin in an in vitro fertilization-embryo transfer program.

Authors:  T Levy; Z Ben-Rafael
Journal:  J Assist Reprod Genet       Date:  1995-04       Impact factor: 3.412

Review 2.  The human menopausal gonadotropin (hMG) dose in in vitro fertilization (IVF): what is the optimal dose?

Authors:  M H van Hooff
Journal:  J Assist Reprod Genet       Date:  1995-04       Impact factor: 3.412

3.  The poor-responder patient in an in vitro fertilization-embryo transfer program.

Authors:  Z Ben-Rafael; D Feldberg
Journal:  J Assist Reprod Genet       Date:  1993-02       Impact factor: 3.412

4.  High-dose follicle-stimulating hormone (FSH) ovarian stimulation in low-responder patients for in vitro fertilization.

Authors:  G E Hofmann; J P Toner; S J Muasher; G S Jones
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-10

5.  Effects of EG-VEGF, VEGF and TGF-β1 on pregnancy outcome in patients undergoing IVF-ET treatment.

Authors:  Min-zhi Gao; Xiao-ming Zhao; Yi Lin; Zhao-gui Sun; Hui-qin Zhang
Journal:  J Assist Reprod Genet       Date:  2012-07-31       Impact factor: 3.412

6.  Use of granulosa-luteal cell culture to evaluate low and high clinical responses to menotropin stimulation.

Authors:  B S Hurst; H A Zacur; W D Schlaff; G D Berkovitz
Journal:  J Endocrinol Invest       Date:  1992-09       Impact factor: 4.256

7.  Clomiphene citrate and hMG: an alternative stimulation protocol for selected failed in vitro fertilization patients.

Authors:  C A Benadiva; O Davis; I Kligman; H C Liu; Z Rosenwaks
Journal:  J Assist Reprod Genet       Date:  1995-01       Impact factor: 3.412

8.  Comparison of GnRh Agonist Microdose Flare Up and GnRh Antagonist/Letrozole in Treatment of Poor Responder Patients in Intra Cytoplaspic Sperm Injection: Randomized Clinical Trial.

Authors:  Azar Nabati; Sepideh Peivandi; Alireza Khalilian; Sina Mirzaeirad; Seyyed Abbas Hashemi
Journal:  Glob J Health Sci       Date:  2015-08-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.